{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:20:54Z","timestamp":1790626854177,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.chest.2021.05.021","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:04:12Z","timestamp":1621382652000},"page":"1614-1623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Managing Corticosteroid-Related Comorbidities in Severe Asthma"],"prefix":"10.1016","volume":"160","author":[{"given":"Vidushi","family":"Sood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.chest.2021.05.021_bib1","first-page":"482","article-title":"Effects of cortisone on bronchial asthma and hay fever occurring in subjects sensitive to ragweed pollen","volume":"25","author":"Carryer","year":"1950","journal-title":"Proc Staff Meet Mayo Clin"},{"issue":"4","key":"10.1016\/j.chest.2021.05.021_bib2","first-page":"340","article-title":"Steroids in respiratory disease","volume":"28","author":"Crompton","year":"1982","journal-title":"Br J Hosp Med"},{"issue":"6947","key":"10.1016\/j.chest.2021.05.021_bib3","first-page":"807","article-title":"Chronic asthma treated with aerosol hydrocortisone","volume":"271","author":"Brebner","year":"1956","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2021.05.021_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaip.2020.06.019","article-title":"Oral corticosteroid treatment patterns of patients in the United States with persistent asthma","volume":"9","author":"Tran","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.chest.2021.05.021_bib5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data From the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2021.05.021_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2021.05.021_bib7","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2021.05.021_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.chest.2021.05.021_bib9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1164\/rccm.201607-1453OC","article-title":"Effects of age and disease severity on systemic corticosteroid responses in asthma","volume":"195","author":"Phipatanakul","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2021.05.021_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2021.05.021_bib11","doi-asserted-by":"crossref","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2021.05.021_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J\u00a0Asthma Allergy"},{"issue":"7","key":"10.1016\/j.chest.2021.05.021_bib13","first-page":"833","article-title":"Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma","volume":"22","author":"Dalal","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.chest.2021.05.021_bib14","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","article-title":"Acute and chronic systemic corticosteroid-related complications in patients with severe asthma","volume":"136","author":"Lefebvre","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.chest.2021.05.021_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/thx.2006.073429","article-title":"Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma","volume":"62","author":"Berry","year":"2007","journal-title":"Thorax"},{"issue":"9171","key":"10.1016\/j.chest.2021.05.021_bib16","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.chest.2021.05.021_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1183\/13993003.00220-2016","article-title":"A\u00a01-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use","volume":"48","author":"van der Meer","year":"2016","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.chest.2021.05.021_bib18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/resp.13134","article-title":"Multidimensional assessment of severe asthma: a systematic review and meta-analysis","volume":"22","author":"Clark","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.chest.2021.05.021_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/JAA.S134300","article-title":"Asthma referrals: a key component of asthma management that needs to be addressed","volume":"10","author":"Price","year":"2017","journal-title":"J\u00a0Asthma Allergy"},{"issue":"4","key":"10.1016\/j.chest.2021.05.021_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"10.1016\/j.chest.2021.05.021_bib21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.chest.2021.05.021_bib22","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.chest.2021.05.021_bib23","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2021.05.021_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2021.05.021_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.chest.2021.05.021_bib26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the \u201creal-world\u201d effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2021.05.021_bib27","doi-asserted-by":"crossref","first-page":"1800948","DOI":"10.1183\/13993003.00948-2018","article-title":"Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma","volume":"53","author":"Busse","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2021.05.021_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2021.05.021_bib29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2021.05.021_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the Asthma Control Test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.chest.2021.05.021_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semarthrit.2016.03.001","article-title":"Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review","volume":"46","author":"Joseph","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.chest.2021.05.021_bib32","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/jc.2015-1218","article-title":"Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis","volume":"100","author":"Broersen","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.chest.2021.05.021_bib33","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1210\/jc.2019-00153","article-title":"Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England","volume":"104","author":"Mebrahtu","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.chest.2021.05.021_bib34","series-title":"Williams Textbook of Endocrinology","first-page":"480","article-title":"The adrenal cortex","author":"Newell-Price","year":"2020"},{"key":"10.1016\/j.chest.2021.05.021_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1210\/jcem-25-3-343","article-title":"Diurnal variation in suppression of adrenal function by glucocorticoids","volume":"25","author":"Nichols","year":"1965","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.chest.2021.05.021_bib36","author":"Furst"},{"issue":"1","key":"10.1016\/j.chest.2021.05.021_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A\u00a0practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.chest.2021.05.021_bib39","doi-asserted-by":"crossref","first-page":"00009","DOI":"10.1183\/23120541.00009-2019","article-title":"Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial","volume":"5","author":"Menzies-Gow","year":"2019","journal-title":"ERJ Open Res"},{"issue":"8","key":"10.1016\/j.chest.2021.05.021_bib40","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2021.05.021_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.chest.2021.05.021_bib43","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4158\/GL-2020-0524","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.chest.2021.05.021_bib44","first-page":"CD005590","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"10","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.chest.2021.05.021_bib45","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamainternmed.2018.5930","article-title":"Further lessons in Pneumocystis pneumonia prophylaxis","volume":"178","author":"Schmajuk","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.chest.2021.05.021_bib46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/archinte.1995.00430110015002","article-title":"Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk","volume":"155","author":"Sepkowitz","year":"1995","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.chest.2021.05.021_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/17476348.2015.1002471","article-title":"Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?","volume":"9","author":"Liebling","year":"2015","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2021.05.021_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.chest.2021.05.021_bib49","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1183\/09031936.97.10071640","article-title":"Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management","volume":"10","author":"Szefler","year":"1997","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2021.05.021_bib50","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/clpt.1990.167","article-title":"Monitoring glucocorticoid therapy: a pharmacokinetic approach","volume":"48","author":"Hill","year":"1990","journal-title":"Clin Pharmacol Ther"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922100948X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922100948X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:38:02Z","timestamp":1757925482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236922100948X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S001236922100948X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2021.05.021","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Corticosteroid-Related Comorbidities in Severe Asthma","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2021.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}